{"id":"glargine-insulin-vs-regular-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:46:56.452975","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs activate insulin receptors on muscle, fat, and liver cells to promote glucose uptake and storage. Glargine insulin has a peakless profile with a duration of ~24 hours, providing steady basal glucose control. Regular insulin has a faster onset (30 minutes to 1 hour) and shorter duration (5-8 hours), making it suitable for mealtime glucose management.","oneSentence":"Glargine insulin is a long-acting basal insulin that binds to insulin receptors to lower blood glucose, while regular insulin is a short-acting insulin with faster onset and shorter duration.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:17.646Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"_fixedFields":["pubmed(27)"],"trialDetails":[{"nctId":"NCT02556840","phase":"NA","title":"Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-25","conditions":"Maturity-Onset Diabetes of the Young","enrollment":46},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07171684","phase":"NA","title":"Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-11-26","conditions":"Diabetes in Pregnancy, Gestational Diabetes","enrollment":176},{"nctId":"NCT05514535","phase":"PHASE3","title":"A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-29","conditions":"Diabetes Mellitus, Type 2, Obesity","enrollment":568},{"nctId":"NCT07224893","phase":"PHASE4","title":"Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management","status":"NOT_YET_RECRUITING","sponsor":"Eastern Virginia Medical School","startDate":"2025-12-01","conditions":"Pregestational Diabetes, Pregnancy","enrollment":200},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT03087032","phase":"PHASE4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2019-01-10","conditions":"Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)","enrollment":164},{"nctId":"NCT06619301","phase":"PHASE3","title":"RCT Glargine vs NPH for Treatment of DM in Pregnancy","status":"RECRUITING","sponsor":"Loyola University","startDate":"2024-04-01","conditions":"Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2","enrollment":160},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT06178874","phase":"NA","title":"Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-12-01","conditions":"Glycemic Control, Insulin, Critical Illness","enrollment":90},{"nctId":"NCT04460326","phase":"PHASE3","title":"Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2020-12-07","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":137},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT02836704","phase":"PHASE4","title":"Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-09","conditions":"Diabetes Mellitus, Type 2","enrollment":892},{"nctId":"NCT04157738","phase":"PHASE4","title":"A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-27","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":24},{"nctId":"NCT01203774","phase":"PHASE4","title":"Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-09","conditions":"Diabetes","enrollment":43},{"nctId":"NCT04739241","phase":"PHASE4","title":"Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Consorci Sanitari Integral","startDate":"2014-01-24","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":60},{"nctId":"NCT04692415","phase":"PHASE4","title":"Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors","status":"COMPLETED","sponsor":"University of Split, School of Medicine","startDate":"2018-12-15","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT01257087","phase":"NA","title":"Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2010-12","conditions":"Type 2 Diabetes Mellitus, Obesity","enrollment":35},{"nctId":"NCT04034524","phase":"","title":"Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2019-05-01","conditions":"Diabetes Mellitus, Type 2","enrollment":20000},{"nctId":"NCT03352674","phase":"PHASE2","title":"Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2016-09","conditions":"Diabetes Mellitus","enrollment":133},{"nctId":"NCT02906917","phase":"PHASE3","title":"A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-09-20","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":532},{"nctId":"NCT02752113","phase":"PHASE3","title":"Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2016-04","conditions":"Diabetes Mellitus Type 2","enrollment":101},{"nctId":"NCT02467920","phase":"PHASE4","title":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":349},{"nctId":"NCT03473262","phase":"","title":"Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2017-01-01","conditions":"Diabetes Mellitus, Type 2","enrollment":200},{"nctId":"NCT00417989","phase":"NA","title":"Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2007-01","conditions":"Type 1 Diabetes","enrollment":485},{"nctId":"NCT02147925","phase":"PHASE4","title":"Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-08","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":75},{"nctId":"NCT01269047","phase":"PHASE4","title":"Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2009-08","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT01680341","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":272},{"nctId":"NCT03463564","phase":"PHASE4","title":"Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2016-01","conditions":"Type 1 Diabetes Mellitus","enrollment":150},{"nctId":"NCT01594060","phase":"PHASE4","title":"Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-06","conditions":"Diabetes Mellitus Type 2","enrollment":36},{"nctId":"NCT02843399","phase":"","title":"Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-08-15","conditions":"Diabetes Mellitus Type 2","enrollment":15498},{"nctId":"NCT01570751","phase":"PHASE3","title":"A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT00855439","phase":"NA","title":"Evaluation of Exenatide in Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2008-06","conditions":"Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy","enrollment":46},{"nctId":"NCT00402909","phase":"PHASE4","title":"Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT02222623","phase":"NA","title":"The Inova Type 2 Diabetes Mellitus Study","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2015-04","conditions":"Diabetes, Type 2","enrollment":""},{"nctId":"NCT00206401","phase":"PHASE4","title":"Lantus in the Treatment of Type 1 Diabetes Children","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-11","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT02540486","phase":"NA","title":"Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2013-12","conditions":"Type 2 Diabetes Mellitus","enrollment":139},{"nctId":"NCT01399645","phase":"PHASE2","title":"Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2011-05","conditions":"Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes","enrollment":35},{"nctId":"NCT01226043","phase":"PHASE4","title":"Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-10","conditions":"Diabetes Mellitus, Type 2","enrollment":405},{"nctId":"NCT00949442","phase":"PHASE4","title":"Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT00562172","phase":"PHASE4","title":"Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Type 2 Diabetes Mellitus","enrollment":75},{"nctId":"NCT01013571","phase":"PHASE4","title":"Self Titration With Apidra to Reach Target Study (START)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":493},{"nctId":"NCT00540709","phase":"PHASE4","title":"PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-11","conditions":"Diabetes Mellitus","enrollment":58},{"nctId":"NCT00857870","phase":"PHASE4","title":"Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2009-03","conditions":"Type 2 Diabetes","enrollment":96},{"nctId":"NCT00384085","phase":"PHASE4","title":"Insulin Glargine \"All to Target\" Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Diabetes Mellitus, Type 2","enrollment":588},{"nctId":"NCT01336751","phase":"PHASE3","title":"Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-07","conditions":"Diabetes Mellitus, Type 2","enrollment":212},{"nctId":"NCT00670228","phase":"PHASE3","title":"Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction","status":"TERMINATED","sponsor":"Sanofi","startDate":"2008-04","conditions":"AMI","enrollment":34},{"nctId":"NCT00708578","phase":"PHASE4","title":"Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus","enrollment":99},{"nctId":"NCT00135096","phase":"PHASE3","title":"Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Diabetes Mellitus, Type 2","enrollment":345},{"nctId":"NCT00046462","phase":"PHASE3","title":"Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-11","conditions":"Diabetes Mellitus","enrollment":240},{"nctId":"NCT00384215","phase":"PHASE4","title":"Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-12","conditions":"Diabetes Mellitus, Type 2","enrollment":352},{"nctId":"NCT00551538","phase":"PHASE4","title":"24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-05","conditions":"Type 2 Diabetes","enrollment":15},{"nctId":"NCT01192711","phase":"PHASE3","title":"Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice","status":"UNKNOWN","sponsor":"Consorzio Mario Negri Sud","startDate":"2009-05","conditions":"Type 1 Diabetes","enrollment":130},{"nctId":"NCT00699686","phase":"PHASE4","title":"Endothelial Effects of Basal Insulin: Detemir Versus Glargine","status":"COMPLETED","sponsor":"University of Padova","startDate":"2008-05","conditions":"Type 2 Diabetes, Endothelial Dysfunction, Cardiovascular Disease","enrollment":50},{"nctId":"NCT00659477","phase":"PHASE4","title":"Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-03","conditions":"Diabetes Mellitus, Type 2","enrollment":117},{"nctId":"NCT00627471","phase":"PHASE4","title":"Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":9},{"nctId":"NCT00348374","phase":"PHASE3","title":"Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-06","conditions":"Diabetes Mellitus","enrollment":191},{"nctId":"NCT00313937","phase":"PHASE4","title":"SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-11","conditions":"Diabetes Mellitus, Type 1","enrollment":91},{"nctId":"NCT00272012","phase":"PHASE3","title":"OPAL - Insulin Glulisine, Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Diabetes Mellitus Type 2","enrollment":396},{"nctId":"NCT00356421","phase":"PHASE4","title":"A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-11","conditions":"Diabetes Mellitus, Type 1","enrollment":58},{"nctId":"NCT00609856","phase":"PHASE4","title":"Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes","status":"COMPLETED","sponsor":"Skane University Hospital","startDate":"2004-04","conditions":"Type 2 Diabetes, Secondary Drug Failure","enrollment":36},{"nctId":"NCT00177398","phase":"PHASE4","title":"Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2005-02","conditions":"Type 2 Diabetes, Hyperglycemia","enrollment":50},{"nctId":"NCT00551356","phase":"PHASE3","title":"Lispro Mix 25 vs. Glargine in Type 2 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-11","conditions":"Diabetes Mellitus Type 2","enrollment":53},{"nctId":"NCT00537251","phase":"PHASE3","title":"32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-11","conditions":"Diabetes Mellitus, Type 1","enrollment":80},{"nctId":"NCT00322075","phase":"PHASE4","title":"LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-04","conditions":"Diabetes Mellitus","enrollment":35},{"nctId":"NCT00222521","phase":"PHASE3","title":"Insulin Glargine Vs Standard Insulin Therapy","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2003-04","conditions":"Cystic Fibrosis Related Diabetes","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"recentPublications":[{"date":"2026 Jan","pmid":"41685005","title":"Effects on Glycaemic Control by Continuous Intravenous Regular Insulin With or Without Subcutaneous Glargine Basal Insulin in Patients With Diabetes Following Coronary Artery Bypass Grafting Surgery.","journal":"Cureus"},{"date":"2025 Nov 7","pmid":"41199369","title":"Early use of neutral Protamine Hagedorn (NPH) insulin in the management of diabetic ketoacidosis: an open-label randomized controlled trial in a resource-limited setting.","journal":"BMC research notes"},{"date":"2025 Jan","pmid":"39802245","title":"Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia.","journal":"Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine"},{"date":"2021","pmid":"34305809","title":"Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial.","journal":"Frontiers in endocrinology"},{"date":"2021 Jun 1","pmid":"34075142","title":"A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care.","journal":"Scientific reports"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Glargine insulin vs regular insulin","genericName":"Glargine insulin vs regular insulin","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glargine insulin is a long-acting basal insulin that binds to insulin receptors to lower blood glucose, while regular insulin is a short-acting insulin with faster onset and shorter duration. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}